Aerobic and Cognitive Training SystemTechnology #ua15-011
Questions about this technology? Ask a Technology Manager
Invention: The invention is a portable system that allows individuals to exercise on aerobic equipment while taking a series of tasks to enhance cognitive function.
• Lack of drugs equates to no unwanted side effects
• Implementation is simpler than a pharmacological therapeutic
• Can be used as a preventative measure as well as a therapeutic measure
Applications: One application for the invention would be as a cognitive enhancer in aging persons. This path is elucidated in the disclosure. Another clinical application would be as potential preventative treatment for Alzheimer’s Disease. There is already evidence that physical exercise plays a role against Alzheimer’s (Radak, et. al). There is potential that adding cognitive exercises will have a positive effect. Evidence also exists to support the sole use of physical exercise as a treatment to stay brain aging (Ahlskog, et. al). Again, adding cognitive exercises may bestow positive effects.
Patent Information: Patent Pending
Birks, J. “Cholinesterase Inhibitors for Alzheimer’s Disease.” Cochrane Database System Review 1 (2006): n. pag. PubMed. Wiley, 25 Jan. 2006. Web. 23 Dec. 2013. <http://www.ncbi.nlm.nih.gov/pubmed/16437532>.
Diaz-Hernandez, J. I., R. Gomez-Villaguentes, M. Leon-Otegui, L. Hontecillias-Prieto, A. Del Puerto, J. L. Trejo, J. J. Lucas, J. J. Garrido, J. Gualix, M. T. Miras-Portugal, and M. Diaz-Hernandez. “In Vivo P2X7 Inhibition Reduces Amyloid Plaques in Alzheimer’s Disease through GSK3β and Secretases.” Neurobiol. Aging 33.8 (2012): 1816-828. PubMed. Elseiver, Aug. 2012. Web. 23 Dec. 2013. <http://www.ncbi.nlm.nih.gov/pubmed/22048123>.
Olivares, D., V. K. Deshpande, Y. Shi, D. K. Lahiri, N. H. Grieg, J. T. Rogers, and X. Huang. “N-methyl D-aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease.” Curr. Alzheimer Res. 9.6 (2012): 746-58. PubMed. Bentham Science, July 2012. Web. 23 Dec. 2013. <http://www.ncbi.nlm.nih.gov/pubmed/21875407>.
Toyohara, Jun, and Kenji Hasimoto. “α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease.” Open Med. Chem. J. 4 (2010): 37-56. PubMed. Bentham Open, 27 May 2010. Web. 23 Dec. 2013. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023065/>.
Name: Gene Alexander
Name: David Raichlen
Name: Paul R. Eynott PhD, MBA